TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the publication of efficacy ...
PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA ...
The first under-the-skin, long-acting risperidone injection offers a new maintenance option for adults with bipolar 1 disorder. For anyone managing bipolar 1 disorder, staying consistent with daily ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Weekly risperidone delivered via the Lynx platform ...
Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...
A final-stage clinical trial comparing a new long-acting, once-weekly pill to treat schizophrenia symptoms with the existing daily treatment has found that both produce comparable therapeutic effects.
LYN-005 is an investigational long-acting oral capsule formulation of the atypical antipsychotic risperidone. Positive data were announced from a phase 3 study comparing the pharmacokinetic (PK) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results